Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma

[1]  S. Jagannath,et al.  Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. , 2022, The New England journal of medicine.

[2]  Shaohua Chen,et al.  Increased TOX expression associates with exhausted T cells in patients with multiple myeloma , 2022, Experimental Hematology & Oncology.

[3]  A. Zahran,et al.  Corrigendum: Higher proportion of non-classical and intermediate monocytes in newly diagnosed multiple myeloma patients in Egypt: A possible prognostic marker , 2021, African Journal of Laboratory Medicine.

[4]  D. Hose,et al.  Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single‐cell transcriptomics , 2021, Nature Communications.

[5]  A. Nafady,et al.  Higher proportion of non-classical and intermediate monocytes in newly diagnosed multiple myeloma patients in Egypt: A possible prognostic marker , 2021, African journal of laboratory medicine.

[6]  M. Arcila,et al.  Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. , 2021, The Lancet. Haematology.

[7]  Shaji K. Kumar,et al.  Microenvironment immune reconstitution patterns correlate with outcomes after autologous transplant in multiple myeloma. , 2021, Blood advances.

[8]  Ariel J. Levine,et al.  Confronting false discoveries in single-cell differential expression , 2021, Nature Communications.

[9]  Raphael Gottardo,et al.  Integrated analysis of multimodal single-cell data , 2020, Cell.

[10]  P. Campbell,et al.  Revealing the impact of structural variants in multiple myeloma. , 2020, Blood cancer discovery.

[11]  M. Nohgawa,et al.  Impact of the CD4:CD8 ratio in bone marrow on stem cell mobilization and engraftment in autologous stem cell transplant patients , 2020, Journal of clinical apheresis.

[12]  Gian Maria Zaccaria,et al.  Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing , 2020, Clinical Cancer Research.

[13]  Michael Brudno,et al.  CReSCENT: CanceR Single Cell ExpressioN Toolkit , 2020, bioRxiv.

[14]  G. Morgan,et al.  Accelerated single cell seeding in relapsed multiple myeloma , 2020, Nature Communications.

[15]  Fei Gao,et al.  PIRD: Pan immune repertoire database. , 2019, Bioinformatics.

[16]  R. Siebert,et al.  Timing the initiation of multiple myeloma , 2019, Nature Communications.

[17]  E. Katodritou,et al.  Evaluation of regulatory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: correlations with treatment outcome , 2019, Annals of Hematology.

[18]  Adeeb Rahman,et al.  Development of a Comprehensive Antibody Staining Database Using a Standardized Analytics Pipeline , 2019, bioRxiv.

[19]  G. Morgan,et al.  Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients , 2019, Haematologica.

[20]  Andrew J. Hill,et al.  The single cell transcriptional landscape of mammalian organogenesis , 2019, Nature.

[21]  S. Mccarroll,et al.  Abstract 139: Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma , 2019, Tumor Biology.

[22]  P. Campbell,et al.  Genomic landscape and chronological reconstruction of driver events in multiple myeloma , 2018, Nature Communications.

[23]  Yuval Elhanati,et al.  OLGA: fast computation of generation probabilities of B- and T-cell receptor amino acid sequences and motifs , 2018, bioRxiv.

[24]  H. Ludwig,et al.  Fixed duration vs continuous therapy in multiple myeloma. , 2017, Hematology. American Society of Hematology. Education Program.

[25]  Jaime Prilusky,et al.  McPAS‐TCR: a manually curated catalogue of pathology‐associated T cell receptor sequences , 2017, Bioinform..

[26]  Andrew K. Sewell,et al.  VDJdb: a curated database of T-cell receptor sequences with known antigen specificity , 2017, Nucleic Acids Res..

[27]  Sin-Ho Jung,et al.  Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Alessandro Sette,et al.  Identifying specificity groups in the T cell receptor repertoire , 2017, Nature.

[29]  N. Munshi,et al.  Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma , 2017, The New England journal of medicine.

[30]  A Orfao,et al.  Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma , 2017, Leukemia.

[31]  R. Fonseca,et al.  Trends in overall survival and costs of multiple myeloma, 2000–2014 , 2016, Leukemia.

[32]  H. Goldschmidt,et al.  International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. , 2016, The Lancet. Oncology.

[33]  B. Storer,et al.  Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamide. , 2016, JCI insight.

[34]  J. P. McCoy,et al.  Standardizing Flow Cytometry Immunophenotyping Analysis from the Human ImmunoPhenotyping Consortium , 2016, Scientific Reports.

[35]  Piet Demeester,et al.  FlowSOM: Using self‐organizing maps for visualization and interpretation of cytometry data , 2015, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[36]  N. Guillaume,et al.  CD14+ CD16+ monocytes rather than CD14+ CD51/61+ monocytes are a potential cytological marker of circulating osteoclast precursors in multiple myeloma. A preliminary study , 2015, International journal of laboratory hematology.

[37]  Yuan-Xiao Zhu,et al.  Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma , 2013, Leukemia & lymphoma.

[38]  Thomas Gebhardt,et al.  Memory T cell subsets, migration patterns, and tissue residence. , 2013, Annual review of immunology.

[39]  M. Beksac,et al.  IMWG consensus on maintenance therapy in multiple myeloma. , 2012, Blood.

[40]  R. Nussenblatt,et al.  Standardizing immunophenotyping for the Human Immunology Project , 2012, Nature Reviews Immunology.

[41]  Davis J. McCarthy,et al.  Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation , 2012, Nucleic acids research.

[42]  Michael L. Wang,et al.  Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. , 2009, Blood.

[43]  F. Schmidt.  Meta-Analysis , 2008 .

[44]  T. Giese,et al.  In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. , 2006, Blood.

[45]  U. Dianzani,et al.  Multiple myeloma: altered CD4/CD8 ratio in bone marrow. , 1990, Haematologica.

[46]  J. Gastwirth.  The Estimation of the Lorenz Curve and Gini Index , 1972 .

[47]  O. Landgren,et al.  MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment. , 2018, Seminars in hematology.

[48]  N. Munshi,et al.  Dysfunctional T regulatory cells in multiple myeloma. , 2006, Blood.